Vertex Q2 revenue beats estimates on strong demand for cystic fibrosis therapies, lifts outlook

Vertex Pharmaceuticals Incorporated

03/08/2026 21:13

Overview
US biotech firm's Q2 revenue rose 12% yr/yr, beating analyst expectations
Adjusted EPS for Q2 met analyst expectations
Company raised full-year 2026 revenue guidance and entered into agreement to acquire Crinetics Pharmaceuticals

Outlook
Vertex raises 2026 revenue guidance to $13.1 bln-$13.2 bln from $12.95 bln-$13.1 bln
Company expects at least $500 mln in 2026 revenue from non-CF products
Vertex reiterates 2026 expense and tax rate guidance; outlook excludes Crinetics acquisition impact

Result Drivers
CF THERAPIES - Continued strong demand for cystic fibrosis treatments, especially ALYFTREK and TRIKAFTA, drove revenue growth
NEW PRODUCT GROWTH - CASGEVY and JOURNAVX posted rapid revenue gains, contributing to diversification beyond CF
INTERNATIONAL EXPANSION - Revenue outside the U.S. rose 14% on strong CF performance, ALYFTREK uptake, increased CASGEVY infusions, and favorable foreign exchange

Company press release: ID:nBw7Fp0Gza

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$3.33 bln
$3.23 bln (24 Analysts)
Q2 Adjusted EPS
Meet
$4.73
$4.73 (20 Analysts)
Q2 EPS
 
$4.31
 
Q2 Adjusted Net Income
Miss
$1.21 bln
$1.23 bln (18 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Vertex Pharmaceuticals Inc is $570.00, about 19.5% above its July 31 closing price of $477.10
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 21 three months ago

Reuters Recommended Reads
Aug 3 - Krystal Biotech Q2 revenue rises on VYJUVEK strength
Aug 3 - Curium strikes up to $8 bln deal for radiopharma peer Lantheus
Aug 3 - TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)